Responses

I would like to submit an FOI request for the following data for Gloucestershire Health and Care NHS Foundation Trust:
1. The number of unique patients with a recorded diagnosis of Dravet syndrome in 2024-2025. Likely coded as ICD-10 code G40.3 or SNOMED code of 230437002, ideally separated by month.
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
2. The number of unique patients with a recorded diagnosis of Lennox-Gastaut syndrome in 2024-2025. Likely coded as ICD-10 code G40.4 or SNOMED code of 230418006, ideally separated by month.
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
3. The number of unique patients who have been treated with fenfluramine in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside fenfluramine, and indicate the number of patients receiving each
4. The number of unique patients who have been treated with cannabidiol in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside cannabidiol, and indicate the number of patients receiving each
5. The number of unique patients who have been treated with cenobamate in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside cenobamate, and indicate the number of patients receiving each
6. The number of unique patients who have been treated with rufinamide in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside rufinamide, and indicate the number of patients receiving each
7. The number of unique patients who have been treated with stiripentol in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside stiripentol, and indicate the number of patients receiving each
8. The number of unique patients who have been treated with clobazam in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside clobazam, and indicate the number of patients receiving each
9. The number of unique patients who have been treated with sodium valproate in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside sodium valproate, and indicate the number of patients receiving each
10. The number of unique patients who have been treated with levetiracetam in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside levetiracetam, and indicate the number of patients receiving each
11. The number of unique patients who have been treated with topiramate in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside topiramate, and indicate the number of patients receiving each
12. The number of unique patients who have been treated with lamotrigine in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
8 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside lamotrigine, and indicate the number of patients receiving each

As part of a piece of work I am undertaking to review the spiritual, religious, and / or chaplaincy services offered by NHS England, I am contacting you to ask for the following information to please be provided.

1. How many whole-time equivalents are employed in the spiritual, religious, and / or chaplaincy service(s) and what are their bandings? Please differentiate between staff on substantive and temporary contracts, as well as staff working in the service on bank or agency contracts.

2. What are the typical core hours of the spiritual, religious, and / or chaplaincy service(s) on offer? How are these service(s) provided over the week (i.e. weekdays only, seven days a week, etc)?

3. What type of support (such as regular activities, events, or gatherings) is offered by the spiritual, religious, and / or chaplaincy service(s)? Please differentiate this between support offered to patients, support offered to family / friends, and support offered to staff members.

4. What on-call or out-of-hours provisions are made by the spiritual, religious, and / or chaplaincy service(s) at your Trust? Please differentiate between provisions offered by staff members employed by the Trust, and provisions offered by external contractors / arrangements.

5. What support is offered to the spiritual, religious, and / or chaplaincy services(s) by external organisations? For instance, what contracts are held by the Trust for this / these service(s) and who are these contracts with?

6. On average, how many service users are supported by the spiritual, religious, and / or chaplaincy service(s) in a week? Please take an average of service users supported between January and December 2024.

7. What is the overall satisfaction for the spiritual, religious, and / or chaplaincy service(s) offered by your Trust? Please provide the overall satisfaction for the period January 2024 to December 2024.

8. What supervision, if any, is provided to staff working in the spiritual, religious, and / or chaplaincy service(s)? Please identify whether this is provided by your Trust or by an external provider, and the average annual cost for this provision.

9. Please provide a contact name and contact email address if there should be any additional queries relating to this Freedom of Information request.

Please can you provide me with the Agency Spend, split between the 3 individual staff groups below :

1. Agency Registered Nurses (all specialities e.g. adult nursing, children’s nursing, community, mental health, midwives, etc) – April 2025
2. Agency Health Care Support Workers – April 2025
3. Agency Doctors – April 2025

This is a request for information under the Freedom of Information Act 2000. I would like to request the following information:

The percentage of patients who met waiting time standards of two weeks between first referral and starting treatment in Early Intervention in Psychosis (EIP) services at Gloucestershire Health and Care NHS Foundation Trust in:

a. 2020/21
b. 2021/22
c. 2022/23
d. 2023/24

I would like to make a request under the Freedom of Information Act relating to Workforce systems
Please respond to the following questions
1. Which software provider does the Trust use for medics rostering software
2. Which software provider does the Trust use for “direct engagement” management of temporary medical staff
3. Which software provider does the Trust use for the management of temporary medical staff
4. Which software provider does the Trust use for master vendor management software
5. What was the annual cost for the Trust’s medics rostering software in the last financial year
6. What is the contractual end date of your current medics rostering software
7. What is the contractual end date of your current direct engagement software
8. What is the contractual end date of your current temporary medical staff management software
9. What is the contractual end date of your current master vendor management software

**Freedom of Information Request: Radiology Equipment and Systems**
I am currently conducting personal academic research on the radiology equipment operated by NHS providers in England. To support this research, I am requesting the following information under the Freedom of Information Act 2000. I kindly ask that the data be provided in an editable digital format (e.g., Excel, Word, or CSV).

Digital X-Ray Systems (static, non-fluoroscopy)
For each system, please provide:
– Hospital where installed
– Make
– Model
– Date installed

CT Scanners
For each system, please provide:
– Hospital where installed
– Make
– Model
– Date installed

MR Scanners
For each system, please provide:
– Hospital where installed
– Make
– Model
– Date installed

Mobile X-Ray Systems
For each system, please provide:
– Hospital where installed
– Make
– Model
– Date installed

Interventional X-Ray Systems (Angiography)
For each system, please provide:
– Hospital where installed
– Make
– Model
– Date installed

Gamma Camera and SPECT-CT Systems
For each nuclear medicine system, please provide:
– Hospital where installed
– Make
– Model
– Year installed

Ultrasound Systems (Radiology)
For each system, please provide:
– Hospital where installed
– Make
– Model
– Year installed

Fluoroscopy Systems
(including remote control, multi-purpose, and under-couch variants)
For each system, please provide:
– Hospital where installed
– Make
– Model
– Year installed

Mobile/Surgical C-Arm Fluoroscopy Systems
For each system, please provide:
– Hospital where installed
– Make
– Model
– Year installed

Under the Freedom of Information Act 2000, I request the following information regarding your use of insourcing for haematology, histopathology, and/or microbiology services between 1 April 2024 and the date of this request (i.e., the last 12 months):

Service Usage:

Does your trust currently use (or has it used in the last 12 months) insourcing providers for any of the following services?

a) Haematology
b) Histopathology
c) Microbiology
d) Oncology
(If yes, please specify which specialties)

Provider Details:

For each insourced specialty above, provide:
a) The name(s) of the external provider(s).
b) The start and end date(s) of the contract(s).

Scope & Volume:

A brief description of the services covered (e.g., “blood film reporting,” “biopsy analysis,” “infection screening”).

Estimated annual spend (or total spend) on these insourcing arrangements for 2023/24.

Procurement Method:
Was the contract awarded via a framework (e.g., NHS SBS DPS, Crown Commercial Service)? If yes, state which one.

If no insourcing is used for these specialties, please state “None.”

Can you please provide the following information under the Freedom of Information Act 2000. This query relates to shopping addiction, which is also known as Compulsive Buying Disorder (CBD) or Oniomania. Could the information please be provided in financial years.

For background, I have been advised that:
• GPs or NHS talking therapies would be the first point of call for such patients.
• Generally those diagnosed with the condition would rarely be diagnosed with it on its own as other mental health problems are likely to be present as well.
• The ICD-11 diagnosis criteria may be used and under that, this condition could be listed as ‘obsessive compulsive disorder – other’ (which was what gambling used to be noted as before it was added to the diagnosis criteria).
1. How many people have been identified as possibly having the condition (Compulsive Buying Disorder – CBD) during the following periods:
a. 2020/21
b. 2021/22
c. 2022/23
d. 2023/24
e. 2024/25
f. 2025-to date
2. What is the age and gender of those mentioned in question 1?
3. If someone presented to the NHS with this condition, what support or treatment options are available?
4. How many people have been identified as having Compulsive Buying Disorder (CBD) alongside another mental health diagnosis? E.g OCD or ADHD.
5. What is the age and gender of those mentioned in question 4?
6. How many people have been identified as having a behavioural addiction e.g gambling, porn or gaming, during the following periods:
a. 2020/21
b. 2021/22
c. 2022/23
d. 2023/24
e. 2024/25
f. 2025-to date
7. What is the age and gender of those identified in question 6?
For questions 2, 5 and 7, I am not requesting any information that would identify patients.

I am writing to make an open government request for all the information to which I am entitled under the FOI Act 2000.

Can you please provide an update on your Trust’s Infrastructure, including aspects of Database software, Wifi coverage, and Virtualisation? The questions are in the attached spreadsheet, which I would be grateful if you could fill in.

I am writing to request information under the Freedom of information act. We are Blayde Security an NHS approved security company under the SBS framework.

We would like to know the following.

Who is the Head of Security for the trust?

Do you use an external provider for your security and if so when does this current contract end?

If this goes back out to tender where will it be advertised?

1. Does your organisation offer salary sacrifice benefits* to staff? If yes, please state the name of the supplier, contract start and end dates.
*salary sacrifice benefit refers to an arrangement where employees agree to give up a portion of their pre-tax salary in exchange for non-cash benefits (e.g childcare, cycle to work schemes) a. Supplier Name b. Contract start date (dd/mm/yy) c. Contract end date (dd/mm/yy)

2. Does your organisation have an external Employee Assistance Programme (EAP)*?
* employee assistance programme refers to an employee-paid confidential service that offers employees support and advice on issues affecting their wellbeing and performance, both personal and work related.
a. If yes, who is the provider?

In accordance with the freedom of information act, please could you answer the following questions:

What EPR (Electronic Patient Record) is currently being used by the Trust?
Are there any plans to change this? If so, when?

Please can you tell me over the last five financial years how many people with a dementia diagnosis have been detained under the Mental Health Act 1983 under section 2 or section 3 of the act. Please specify whether section 2 or section 3 was used.

Please specify where each person was detained i.e. name of ward

I’m writing on behalf of Systech Innovations to request the following information under the Freedom of Information Act, relating to your organisation’s data storage for digitised patient records:

1. What system is used to store image files (i.e. records which have been scanned and digitised)?
2. The current total amount of data stored in the system. Please provide this in terabytes (TB).
3. The volume of data added to the system annually for the past two years (2022/23 and 2023/24), with figures in TB.
4. The hosting environment used for the system (e.g. on-premise, local cloud, or external private cloud).
5. The total amount of data that has been deleted from the system since its initial implementation, also in terabytes.

I am writing to request the following information under the Freedom of Information Act 2000.

1. Does your trust have any specific clinical care pathways, protocols, or service guidance specifically for the treatment or management of patients with:

Dissociative disorders (including DID, OSDD, DPDR etc..)?
Complex post-traumatic presentations involving dissociation?

2. If yes, please provide copies of any relevant documentation or pathway flowcharts.

3. Which clinical teams or services (e.g. CMHTs, trauma services, personality disorder services, psychology/psychotherapy teams) typically provide care for patients with dissociative disorders and dissociative presentations?

4. Does your Trust offer or commission any specialist assessment or treatment (e.g. SCID-D diagnostic assessment) specifically for dissociative disorders?

5. Are patients with dissociative disorders referred to external providers (e.g. Centre for Dissociative Studies, Pottergate Centre, or other independent services)? If so, under what circumstances?

6. Has your Trust delivered any training or guidance for clinicians on dissociative disorders in the past five years?

7. If possible, please provide the number or percentage of current patients under your care who have a diagnosis of a dissociative disorder. This may include conditions coded under ICD-10 (eg. F44.8), ICD-11 (e.g. 6B64) or equivalent SNOMED CT terms. (If your trust uses other diagnostic classification systems such as DSM, please indicate where applicable.)

Please confirm the Trust holds the following data and where it is held; please provide the data as requested.

Questions

Do you offer Tier 3 weight management services (sometimes called specialist weight management services)? (Yes/No)

If yes, do you offer consultant-led Tier 3 weight management services? (Yes/No)

For each non-consultant-led Tier 3 weight management service:

How many patients were waiting for treatment at the start of April 2024?

How many referrals to the Tier 3 weight management service were received per month from April 2024 to March 2025?

How many patients started treatment per month from April 2024 to March 2025?

For each consultant-led Tier 3 weight management service:

Please confirm whether these referrals and activity are submitted in the Trust’s RTT submissions.

Please confirm which Treatment function code (TFC) is used for this activity.

How many patients were waiting for treatment at the start of April 2024?

How many referrals were received per month from April 2024 to March 2025?

How many clock starts were there per month from April 2024 to March 2025

What are the mechanisms used to record clock stops/first definitive treatments (e.g. appointment, information provided etc)?

Please provide the number of clock stops per month by mechanism from March 2024 to April 2025